# 2018 Annual San Antonio Drug Discovery Symposium

**April 12-13, 2018**

Greehey Children’s Cancer Research Institute, UT Health San Antonio

## Thursday, April 12

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM-8:30 AM</td>
<td>Continental Breakfast and Registration</td>
<td></td>
</tr>
</tbody>
</table>
| 8:30 AM-8:45 AM | Welcome from Symposium Co-Chairs                                                                 | Matthew J. Hart, Ph.D., Director, Center for Innovative Drug Discovery High Throughput Screening Core Facility, UT Health San Antonio  
Stanton F. McHardy, Ph.D., Co-Director, Center for Innovative Drug Discovery, Director, Max and Minnie Tomerlin Voelcker Medicinal Chemistry Core Facility, UTSA |
| 8:45 AM-9:00 AM | Introductory remarks                                                                             | TBD                                                                              |
| 9:00 AM-9:50 AM | Plenary Keynote Presentation                                                                     | Session Chair: Jenny Hsieh, PhD                                                  |
| 9:00 AM-9:50 AM | Lawrence Goldstein, PhD, UC San Diego                                                            | **Stem Cells & Aging**                                                          |
| 9:50 AM-10:10 AM| Coffee Break                                                                                     |                                                                                  |
| 10:10 AM-11:40 PM | Session One                                                                                      | Session Chair: Stanton McHardy, PhD                                             |
|                | **New Approaches to Target Identification**                                                     |                                                                                  |
|                | Jenny Hsieh, PhD, UTSA                                                                          | **Precision Models of Brain Disorders for Drug Discovery**                      |
|                | **Marty Matzuk, MD, PhD, Baylor College of Medicine**                                            | **DNA Encoded Libraries**                                                       |
|                | Daniel Nomura, PhD, UC Berkeley                                                                  | **TBD**                                                                         |
| 11:45 PM-1:15 PM | Lunch and Posters/Vendor Session 1                                                               |                                                                                  |
| 1:15 PM-3:45 PM | Session Two                                                                                      | Session Chair: Matthew J. Hart, PhD                                             |
|                | **Addressing Challenging Drug Targets**                                                          |                                                                                  |
|                | Kevin Dalby, PhD, UT Austin                                                                      | **Discovery of a Novel ERK Inhibitor with Activity in BRAF Mutant Melanoma Models** |
Alemayehu (Alex) Gorfe, PhD, University of Texas Health Houston
*Computation-driven discovery of novel K-Ras inhibitors*

Karen Vasquez, PhD, UT Austin
*Molecular probes to interrogate roles of non-B DNA structures in DNA damage and genetic instability*

3:45 PM-4:00 PM  Coffee Break

4:00 PM-5:20 PM  Session Three
*Drug Discovery and Development at UT Health San Antonio/UTSA*  
Session Chair: Bruce Nicholson, PhD

Rong Li, PhD, UT Health San Antonio  
Professor, Molecular Medicine  
Holder of the Tom C. & Patricia H. Frost Endowment
*Rallying the Antitumor Activity of Estrogen Receptor beta*

Paul Hasty, PhD, UT Health San Antonio  
Professor, Molecular Medicine
*TREX2 inhibitors reduce the level of mutations in cells defective for homologous recombination and mismatch repair*

Stan McHardy, PhD, UTSA
*Synthesis and SAR of New Natural Product-Based Diaryloxazoles with Selective Activity against Androgen Receptor-Positive Breast Cancer Cells*

5:20 PM-7:00 PM  Wine and Cheese Social

---

**Friday, April 13**

8:00 AM-8:30 AM  Continental Breakfast

8:30 AM-10:30 AM  Poster/Vendor Session 2

9:00 AM-10:30 AM  **CIDD EAB and IAB meeting (Biggs conference room, GCCRI)**

10:30 AM-12:00 PM  Session Four  
Session Chair: Stan McHardy, PhD
*Neurological Disease*

Jotham Coe, PhD, Pfizer  
*Nicotine Meet’s its Match? . . . The Discovery of Varenicline*

Ivy Carroll, PhD, RTI International  
*Design, Synthesis and In Vitro Pharmacological Evaluation of Novel Kappa Opioid Receptor Antagonists*

Adron Harris, PhD, Associate Director, Waggoner Center for Alcohol & Addiction Research  
Professor of Neuroscience, Psychiatry and Pharmacology  
M. June & J. Virgil Waggoner Chair in Molecular Biology  
UT Austin  
*Transcriptomic and Bioinformatic Approaches for Pharmacotherapy of Alcohol Use Disorders*

12:00 PM-1:30 PM  Lunch/Vendor

1:30 PM-3:20 PM  Session Five  
Session Chair: Rong Li, PhD
*Oncology and Immuno-Oncology*

Brian Blagg, PhD, Notre Dame University  
*Targeting the Hsp90 Molecular Chaperone for the Treatment of Cancer and Other Diseases*
Jim Rizzi, PhD, Peleton

*Discovery of PT2385, a first-in-class HIF-2α inhibitor for the treatment of renal cell carcinoma*

Tyler Curiel, MD, UT Health San Antonio

*Tumor cell-intrinsic Ig superfamily signals as novel cancer drug discovery targets: PD-L1/PD-1 signals as the test case*

Alex Pertsemlidis, PhD, UT Health SA, GCCRI

*Title*

3:20 PM-3:35 PM  
**Coffee Break**

3:35 PM-4:35 PM  
**Session Six**  
*Cardiovascular and Metabolic Diseases*

Stefano Tiziani, PhD, UT Austin

*High-content metabolomic screening in biomarker discovery and therapeutic treatment*

Harshini Neelakantan, PhD, UT Medical Branch

*Small molecule NNMT inhibitors: An adipose-centric approach to combat metabolic diseases*

4:35 PM  
**Closing Remarks**  
Bruce Nicholson, PhD  
Co-Director, Center for Innovative Drug Discovery  
Chairman, Department of Biochemistry and Structural Biology  
UT Health San Antonio